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Effects of vitamin D metabolites on protein catabolism of muscle from
uremic rats. Epitrochlearis muscles obtained from normal male
Sprague-Dawley rats used as controls (C) and rats with reduced renal
mass (Nx) were incubated for 1 hr in Krebs-Ringer buffer containing
5 mM glucose with or without insulin, 25-hydroxycholecalciferol
[25(OH)D11 or 1,25 dihydroxycholecalciferol [l,25(OH)2D3]. Plasma
levels of 25(OH)D3 were unaffected by reduction in renal mass. Alanine
(ALA), tyrosine (TYR), and phenylalanine (PHE) release rates from
muscles of Nx rats were increased 40% above C values. Addition of 100
nglml of 25(OH)D3 to the incubating media reduced these release rates
to C values within 1 hr of incubation. No additive effects with insulin
were seen. Addition of 1 nglml of 1,25(OH)2D3 did not affect these
results. Reduction of renal mass or the addition of insulin or 25(OH)D3
did not affect tissue concentrations of ATP or phosphocreatine. On the
other hand, tissue levels of TYR and PHE were increased significantly
(' 20 to 25%) in muscles from Nx rats compared to C values and were
reduced to control values by the addition of 25(OH)D3. The addition of
insulin to the incubating media reduced the tissue levels of TYR and
PHE in muscles of C rats by 20%, but reduced these levels in muscles
of Nx rats by 55%. 25(OH)D3 did not affect tissue levels of cyclic
AMP in muscles from either C or Nx rats. Protein synthetic rates were
reduced significantly in muscles from Nx rats and returned to C values
after 3 hr of incubation but were unaffected by 25(OH)D3. Muscle
uptake of 3H,25(OH)D3 was reduced by 30% in muscles from Nx rats
compared to C rats. These data suggest that increased muscle protein
catabolism exists in rats with reduced renal mass which can be reduced
to C values by 25(OH)D3 and does not appear to be mediated through
stimulation of adenylate cyclase. 25(OH)D3 did not affect muscle
protein synthetic rates. Reduced uptake of 3H,25(OH)D3 by muscles of
Nx rats suggests that resistance to this vitamin metabolite may exist at
the level of muscle in uremia.
Les effets des métabolites de Ia vitamine D sur le catabolisme protéique
du muscle de rats urémiques. Des muscles épitrochléens provenant de
rats normaux males Sprague-Dawley utilisés comme contrôles (C) et de
rats avec une masse rénale réduite (Nx) ont été incubés pendant 1 heure
dans du tampon Krebs-Ringer contenant 5 mrvt de glucose avec ou sans
insuline, du 25-hydroxycholecalciferol [25(OH)D3] ou du I ,25-dihy-
droxycholécalciférol [1 ,25(OH)2D3]. Les concentrations plasmatiques
de 25(OH)D3 n'étaient pas modifiées par la reduction de la masse
rénale. Les vitesses de relargage de l'Alanine (ALA), de la tyrosine
(TYR), et de la phenylalanine (PHE) a partir des muscles des rats Nx
étaient augmentées de 40% au-dessus des valeurs C. L'addition de 100
nglml de 25(OH)D3 aux milieux d'incubation a réduit ces vitesses de
relargage aux valeurs C en 1 heure d'incubation. Aucun effet additif n'a
Cté observe avec l'insuline. L'addition de I nglml de 1 ,25(OH)2D3 n'a
pas modiflé ces résultats. La reduction de la masse rénale ou l'addition
d'insuline 00 de 25(OH)D3 n'a pas modiflé les concentrations tissulaires
d'ATP ou de phosphocréatine. D'un autre côté, les concentrations
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tissulaires de TYR et de PHE étaient significativement augmentées (
20 a 25%) dans les muscles de rats par rapport aux valeurs C et étaient
ramenées aux valeurs contrOles par l'addition de 25(OH)D3. L'addition
d'insuline aux milieux d'incubation a réduit les concentrations tissu-
laires de TYR et PHE dans les muscles de rats C de 20%, mais a
réduit ces concentrations dans les muscles des rats Nx de 55%. Le
25(OH)D3 n'a pas modifld les concentrations tissulaires d'AMP cy-
clique dans les muscles de rats C ou Nx. Les vitesses de synthese
protéiques ëtaient significativement réduites dans les muscles de rats
Nx, et revenaient aux valeurs C apres 3 heures d'incubation, mais
n'étaient pas modifiées par le 25(OH)D3. La captation musculaire de
3H,25(OH)D1 dtait réduite de 30% dans les muscles de rats Nx par
rapport aux rats C. Ces données suggèrent qu'un catabolisme muscu-
laire protéique accru existe chez des rats avec une masse rCnale réduite,
et quit peut être ramené aux valeurs C par te 25(OH)D1 et ne semble
pas médié par Ia stimulation de l'adenylate cyclase. Le 25(OH)D3 na
pas modiflé les vitesses de synthese protéique musculaire. Une capta-
tion réduite de 3H,25(OH)D3 par les muscles de rats Nx suggére que La
résistance a ce métabolite vitaminique pourrait exister au niveau du
muscle dans l'urémie.
Previous studies from our laboratory [11 demonstrated that a
reduction in renal mass in the rat is associated with an augment-
ed release of alanine, tyrosine, and phenylalanine from the
epitrochlearis muscle studied in vitro. As the protein content of
the diets was increased from 10 to 40%, growth rates in the
uremic rats approached control values, and there was de-
creased release from muscle of the noncatabolizable amino
acids, tyrosine, and phenylalanine. However, at all levels of
protein intake the release of these amino acids from muscles
obtained from uremic rats remained significantly above control
values. Of interest, alanine release from muscles obtained from
uremic rats increased as protein intake increased. The addition
of insulin to the incubating media reduced the release of
tyrosine and phenylalanine toward control values. These data
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suggest that uremia is a catabolic state typified by increased
amino acid release from muscle which can be at least partially
suppressed by increasing dietary protein intake or by adding
insulin to the incubating media.
Uremia is also associated with alterations in parathyroid
hormone [21 and vitamin D [3] metabolism. Relatively early in
the course of progressive renal insufficiency, plasma PTH
levels increase despite normal circulating concentrations of
both 25-hydroxycholecalciferol and 1,25 dihydroxycholecalcif-
erol [2—4]. This secondary hyperparathyroidism is associated
with reduced intestinal absorption of calcium and blunted
responsiveness of bone to parathyroid hormone [5]. As the
GFR falls below 40 mI/mm, serum levels of 1,25 dihydroxycho-
lecalciferol decrease [61 while 25 hydroxycholecalciferol levels
remain unaltered [3, 7].
Studies by Birge and Haddad [8] utilizing the rachitic rat
model have shown that 25-hydroxycholecalciferol enhances
leucine incorporation into muscle protein after 4 to 5 hr of
incubation and increases the levels of ATP in the cell. 1,25
dihydroxycholecalciferol did not affect these parameters. Other
studies demonstrate that tension generated by the triceps surae
muscle obtained from rachitic chicks and studied in vitro is
reduced but returns to normal if vitamin D, but not calcium, is
added to the diet [9]. This increased muscle tension is associat-
ed with increased mitrochondrial calcium content and a more
rapid uptake of calcium by sarcoplasmic reticulum [9]. Subse-
quent studies designed to dissociate the effects of 1,25 dihy-
droxycholecalciferol from 25-hydroxycholecalciferol on muscle
suggest that only the latter metabolite is capable of stimulating
calcium uptake by the sarcoplasmic reticulum [10]. On the other
hand, other studies suggest that a direct effect of 1,25 dihy-
droxycholecalciferol on calcium uptake by the sarcoplasmic
reticulum exists [11].
Thus, it appears that vitamin D, and more specifically, 25-
hydroxycholecalciferol enhances protein synthesis in muscle of
rachitic rats and may affect growth and muscle function in
normal and rachitic animals. The effects of the various vitamin
D metabolites on uremic muscle are unknown. These studies
were designed, therefore, to evaluate the effects of 25-hydroxy-
cholecalciferol and 1,25 dihydroxycholecalciferol on catabolism
and synthesis of protein in muscle obtained from rats with
reduced renal mass.
Methods
Male Sprague-Dawley rats weighing 110 to 140 g were used
for these studies. All animals were housed in individual meta-
bolic cages under constant humidity and temperature and were
pair-fed Purina rat chow (Ralston Purina Co., St. Louis, Mis-
souri) as previously described [1], and received one-quarter
normal saline as the drinking solution [12]. Renal mass was
reduced as previously described from this laboratory [1]. Be-
cause the animals with reduced renal mass (Nx) ate at a slower
rate, sham-operated pair-fed control animals (C) were fed
their diet in two divided quantities, morning and evening. The
weight of the Nx animals was 127 4 g compared to C animals,
139 6 g (P < 0.05). Studies were performed in the fed state 10
days after surgery.
Experimental Procedure
Release of amino-acids from muscle. On the morning of the
study, blood samples were obtained from a representative
number of rats for the determination of plasma creatinine and
urea, to document the degree of reduction in renal function.
Levels of plasma 25-hydroxycholecalciferol [25(OH)D3], calci-
um, and phosphate were also determined. The rats were then
killed by a blow to the head and the lumbar vertebral column to
prevent muscle spasm. The epitrochlearis muscles were re-
moved rapidly, washed in Saline-Krebs-Ringer bicarbonate
buffer at pH 7.4, blotted, and then placed in 500 d of the
incubating media. The incubating media for all the experiments
of amino acid release were freshly prepared on the day of the
study and contained Krebs-Ringer bicarbonate buffer to which
were added glucose and Hepes buffer at a final concentration of
5 mM each as previously described [1]. Where specified,
purified, glucagon-free, porcine insulin (Eli Lilly and Co.,
Indianapolis, Indiana, lot #6l5-D63-l0) was added in a final
concentration of 0.01 t/ml. Where specified 25(OH)D3 (Upjohn
Company, Kalamazoo, Michigan, lot #17-733) was added in a
final concentration of 100 ng/ml. 1,25 dihydroxy cholecalciferol
[l,25(OH)2D3] (Hoffman-LaRoche Co., Nutley, New Jersey,
lot #5374-25) was added in a final concentration of 1 ng/ml. All
media contained 1 mg/mI of purified bovine serum albumin
(Sigma, St. Louis, Missouri) and the vehicle, propylene glycol
(1.4 mM). Muscles from Nx animals were assigned randomly to
each treatment group. One muscle from each rat was incubated
with insulin or the vitamin D metabolite and the other muscle in
medium alone. Studies were also performed using both insulin
and the vitamin D metabolite to document the combined effect
of these hormones.
The muscles were incubated for 1 hr using continuous 95%
02, 5% CO2 bubbling in a metabolic shaker at 37°C. The
muscles were removed after incubation, blotted, and then
frozen in liquid nitrogen. The incubating media were heated for
2 mm at 90°C to inactivate any enzymes released from the
muscle [13]. Both the media and muscles were maintained at
—80°C until the assays were performed. The amounts of ala-
nine, tyrosine, and phenylalanine released were determined for
each muscle as previously described [1]. All release rates are
expressed as nanomoles per gram wet weight per minute.
Tissue pool sizes for ATP, phosphocreatine, tyrosinè, and
phenylalanine were determined for each muscle as previously
described [1]. Intracellular substrate levels are expressed as
nanomoles per milligram wet weight. The ratio of milligrams of
muscle protein to milligrams of wet weight of muscle was
unaffected by reduction in renal mass or addition of 25-OH
cholecalciferol to the incubating media.
Leucine incorporation studies. The rats were prepared, fed
standard rat chow, and the epitrochlearis muscle was removed
as outlined above. Standard media were used for all experi-
ments and contained 0.6 Ci/ml of L (4-5-H3) leucine (Amer-
sham Co., London, England) 149.5 Ci/mmole) and an amino
acid mixture containing 16 essential and nonessential amino
acids in a final concentration of 1.0 m each. Where specified,
the media contained 25(OH)D3 in the concentrations outlined
above. Incubations were continued for 1, 3, or 5 hr. In a
representative number of muscles, leucine pool sizes were
determined after 1 hr of incubation.
At the termination of the incubation, the epitrochlearis mus-
cles were removed, rinsed, and then homogenized in 500 l of
cold 5% perchloric acid (PCA) with a Teflon pestle tissue
grinder. The precipitated protein was washed with an additional
50 l of 5% PCA and then dissolved in KOH for determination
of radioactivity and Lowry protein measurements [14]. The
radioactivity of the preparation was measured in a Tricarb
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Liquid Scintillation Spectrometer (Packard Instrument Co.,
Downers Grove, Illinois). All data are expressed as disintega-
tions per minute (dpm) per milligram protein (Lowry method).
Cyclic AMP studies. The rats were prepared, fed standard rat
chow, and the epitrochlearis muscle was removed as described
above. Standard media were used for all studies and where
specified contained 100 nglml of 25(OH)D3 as well as isobutyl-
methyixanthine (IBMX) or IBMX alone in a final concentration
of 1 mM. All incubations were carried out for 1 or 3 hr. At the
termination of the experiment the muscles were removed,
blotted, and then homogenized in 500 d of cold 5% trichiorace-
tic acid (TCA) using a Teflon glass tissue grinder. One picomole
of 3H cyclic AMP was added to the media to document
recovery of cyclic AMP. The homogenate was centrifuged at
x2000g for 15 mm, and the supernatant was extracted with
ether to remove the TCA and then lyophilized and reconstituted
in 50 m sodium acetate at pH 6.2. Tissue cyclic AMP was then
assayed using a radioimmunoassay as previously described
from this laboratory [15]. The results are given in pmoles/lOO
mg wet weight of muscle.
Muscle uptake of 25(OH)D3. To measure the ability of muscle
to accumulate 25(OH)D3, 8 ng of 25-(26,27,methyl-3H)-hydroxy
cholecalciferol [3H-25(OH)D31, 23 Cilmmole (Amersham, Ar-
lington Heights, Illinois) were given intravenously through the
tail vein in 0.3 ml of rat serum to both C and Nx rats. Four hours
after administration of the label, the animals were anesthetized
with ether, and then blood was sampled from the heart. The
abdominal aorta was bisected and the inferior segment perfused
with saline until the effluent from the bisected inferior vena
cava was clear. Muscle from both lower extremities was
removed and homogenized in a Virtis homogenizer. The muscle
homogenate was extracted twice with chloroform and methanol
in a ratio of 2:1:1 of homogenate. Radioactivity of the serum
and an aliquot of the lipid extract, evaporated to dryness under
nitrogen, was measured by liquid scintillation spectrometry. An
aliquot of the lipid extract of muscle was also applied to a
microporasil column and eluted with hexane:isopropanol, 9:1 in
a high performance liquid chromatographic system (Waters,
model 440).
Assays. Plasma creatinine, urea, calcium, and phosphate,
were determined by techniques previously described from this
center [17]. Alanine was assayed using a modified microfluoro-
metric technique [181, and both tyrosine and phenylalanine
using a modified transfer RNA method as originally described
by Rubin and Goldstein [191. Tissue pool sizes for ATP,
phosphocreatine, tyrosine, and phenylalanine were assayed as
previously described [11. Tissue leucine was assayed using a
modified transfer RNA method [19].
Reagents. Adenylate kinase (EC 2.7.4.3), glucose-6-phos-
phate dehydrogenase (EC 1.1.1.49), hexokinase (EC 2.7.1.1),
alanine aminotransferase (EC 2.6.1.2), NAD+, NADH,
NADP+, and T-RNA were obtained from the Sigma Chemical
Company (St. Louis, Missouri).
Statistics. Statistical data were generated using the Student's
tests for paired and nonpaired samples where appropriate. All
data are presented as mean SEM.
Results
Table I summarizes the data on the plasma levels of urea,
creatinine, calcium, phosphate, and 25(OH)D3 in C and Nx rats.
The plasma levels of BUN and creatinine were significantly
higher in the Nx rats compared to C (P < 0.01) indicating that
significant uremia was induced. The plasma levels of calcium
were significantly lower (P < 0.05) and phosphate higher (P <
0.05) in Nx compared to C groups. The plasma levels of
25(OH)D3 were not significantly different in the two groups and
were within the normal range for our laboratory [17].
Release rates of alanine. Figure 1 depicts the effects of 100
nglml of 25(OH)D3 on the rates of alanine release from muscle.
Muscles (N = 16) from Nx rats had a significantly greater
release of alanine when compared to muscles from pair-fed C
rats (P < 0.01). When 25(OH)D3 was added to the media, these
increased release rates returned to control values within 1 hr of
incubation. 25(OH)D3 did not affect alanine release from mus-
cles of control animals. No added effects were seen when
insulin was added to the media together with 25(OH)D3. The
addition of 1 nglml of 1,25 di-(OH)D3 to the incubating media
did not affect the release rates of alanine from muscles of C or
Nx rats, while insulin significantly reduced these rates from
muscles of Nx rats (28.4 2.6 nmoles/g wet weight/mm and
22.3 1.8 nmoles/g wet weight/mm with the addition of insulin,
P < 0.05).
Release rates of tyrosine and phenylalanine. Figure 2 out-
lines the effects of 25(OH)D3 and insulin on the release of
tyrosine and phenylalanine from muscles (N = 12) obtained
from C and Nx rats. Baseline release rates of tyrosine and
phenylalanine were significantly greater from muscles of Nx
compared to C rats (P < 0.01) and were positively correlated
with the increased tissue pool sizes of these two amino acids
(Table 2). After 1 hr of incubation with the addition of 100 ng/ml
of 25(OH)D3, these release rates returned toward control values
which were associated with a reduction in pool size of the
amino acids to control values (Table 2). No added effects of
insulin were seen with phenylalanine release but an additive
effect was seen with tyrosine release (tyrosine release de-
creased from 1.8 0.1 to 1.0 0.1 nmoles/g wet weight/mm
when insulin was added to the media, P < 0.05). Of interest, the
addition of both 25(OH)D3 and insulin significantly reduced the
release of phenylalanine from muscles obtained from C rats (1.5
0.06 to 0.9 0.08 nmoles/g wet weight/mm (P < 0.05).
When 1 ng/ml of l,25(OH)2D3 was added to the media, no
changes in tyrosine release from muscles from Nx rats were
seen after 1 hr of incubation (N = 12) (Fig. 3). Insulin
significantly reduced tyrosine release from muscles of Nx rats
from 2.8 0.2 to 2.0 0.1 nmoles/g wet weight/mm (P < 0.01)
although these rates did not return to control values (1.5 0.1
nmoles/g wet weight/mm). Phenylalanine release from muscles
from Nx rats was unaffected by the addition of 1 ,25(OH)2D1
while insulin reduced these rates to control values.
Leucine incorporation. Previous studies by Garber [20] have
shown decreased protein synthesis in muscle from uremic rats
which is corrected by supraphysiologic concentrations of insu-
lin. To evaluate the effects of 25(OH)D3 on protein synthesis by
muscle, 100 ng/ml of 25(OH)D3 were added to the incubating
media and leucine incorporation was determined after 1, 3, and
5 hr of incubation. The data are depicted in Figure 4. Leucine
incorporation into muscles from C rats was unaffected by
25(OH)D3. Of interest, protein synthetic rates of muscles from
Nx rats were depressed significantly after 1 hr of incubation
(402 33 cpm/mg protein) as compared to muscles from control
rats (530 47 cpmlmg protein, P < 0.05). Pool sizes for leucine
were determined in eight muscles from each group after 1 hr of
incubation. Muscles from C rats had levels of 68.64 4.81
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Table 1. Plasma levels of calcium, phosphate, BUN, creatinine and 25-OH cholecalciferol in C and Nx rats
25-OH
Calcium Phosphate Creatinine BUN Cholecalciferol
ng/mlmg/dl
C (18) 10.8 0.1 8.1 0.2 0.45 0.01 15.6 0.6 12.1 1.4
Nx (18) 9.2 06 8.9 O.2 1.11 004b 56.6± 37b 1.5
Abbreviations and symbol: C, control rats; Nx, partially nephrectomized rats; ( ), refers to the number of animals in each group.
a P < 0.05 compared to C values.
b P < 0.01 compared to C values.
Baseline 25-OH 25-OH
Cholecalciferol Cholecalciferol
+ Insulin
Fig. 1. Release rates of alanine from epitrochlearis muscles obtained
from control and partially nephrectomized rats with and without
the addition of 100 nglml of 25-OH cholecalciferol or 100 nglml of 25-
OH cholecalciferol and 0.01 ,iiml of insulin.
nmoles/mg wet weight while the levels in muscles from Nx rats
were 52.98 6.79 nmoles/mg wet weight, P < .0.05. Addition
of 25(OH)D3 did not significantly alter the leucine levels in
muscles from C rats (63.04 3.95 nmoles/mg wet weight) but
did increase the levels in muscles from Nx rats (65.56 3.63
nmoles mg wet weight, P < 0.05). After 3 hr of incubation, the
synthetic rates in muscles from Nx rats increased to values
comparable to C values, which were unaffected by the addition
of 25(OH)D3.
Tissue pool sizes. Tissue pool sizes for ATP, phosphocreati-
nine, tyrosine, and phenylalanine were determined in a repre-
sentative number of muscles from C and Nx animals as outlined
in Table 2. Reduction of renal mass did not affect cellular ATP
or phosphocreatine levels when compared to control values
after 1 hr of incubation. The addition of 25(OH)D3 or insulin did
not affect tissue ATP levels. When both insulin and 25(OH)D3
were added to the media, tissue phosphocreatinine levels were
increased significantly in muscles from C and Nx rats compared
to baseline data (P < 0.05). On the other hand, the tissue pool
sizes for tyrosine were significantly greater in the Nx muscles
compared to C (56.5 5.43 vs. 42.78 6.91 nmoles/mg wet
weight, P < 0.02). While the phenylalanine levels were also
higher in Nx muscles compared to C, the difference did not
reach statistical significance (41.28 3.01 vs. 33.91 4.34
nmoles/mg wet weight). Of interest, when 25(OH)D3 was added
to the media, tyrosine pool sizes decreased from 42.78 6.91 to
33.8 4.48 nmoles/mg wet weight in C muscles (P < 0.05) and
from 56.5 5.43 to 34.58 5.57 nmoles/mg wet weight in Nx
muscles (P < 0.02). The tyrosine pool size in C muscles was
27.05 5.5 nmoles/mg wet weight after the addition of insulin
to the incubating media. No additive effects were seen when
insulin and 25(OH)D3 were combined (24.33 2.97 nmoles/mg
wet weight). The addition of insulin to the media reduced
tyrosine pooi size to 25.75 4.22 nmoles/mg wet weight in
muscles obtained from Nx rats. No added effects were seen
when insulin and 25(OH)D3 were added together (31.28 3.74
nmoles mg/wet weight). Changes in the phenylalanine pool
sizes in response to 25(OFI)D3 and insulin were similar to those
of tyrosine with one exception. In muscles from C rats,
reduction of the phenylalanine pool was significantly greater
with the addition of both 25(OH)D3 and insulin to the incubation
media than with the addition of either agent separately (P <
0.02).
Tissue cyclic AMP levels. Table 3 depicts cyclic AMP levels
in muscles obtained from C and Nx rats. As can be seen, no
significant differences in muscle cyclic AMP levels were noted
after I or 3 hr of incubation with or without the addition of
25(OH)D3.
Muscle uptake of 25(OH)D3. Uptake of 3H-25(OH)D1 by
muscles obtained from Nx rats was compared to that in C rats
(Table 4). Four hours after administration of the tracer, blood
levels of 3H-25(OH)D3 were significantly increased in the
uremic animals, whether expressed per milliliter of serum (P <
0.01) or per milliliter of serum corrected for body weight (P <
0.05) to correct for the smaller volume of distribution in the
uremic animals. Clearance of 3H-25(OH)D3 by muscle from
plasma was determined to correct for the higher concentrations
of the tracer in plasma. Despite the apparent increased avail-
ability 3H-25(OH)D3 in the uremic animals, muscle accumula-
tion and clearance of the label was reduced significantly (P <
0.01). High performance liquid chromatographic analysis con-
firmed that 99% of the chloroform-methanol extracted radioac-
tivity in muscle was 25(OH)D3.
Discussion
Chronic renal disease may be complicated by varying degrees
of myopathy characterized by both a decrease in muscle
strength 2lJ and muscle mass [221. The pathogenesis of this
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Table 2. The effects of 25-OH cholecalciferol and insulin on tissue pool sizes of ATP, phosphocreatine (PCR), tyrosine (TYR), and
phenylalanine (PHE) in muscles from C and Nx rats after 1 hr of incubationa
ATP PCR TYR PHE
C
+25-OH
(10)
(8)
4.89 0.49
4.62 0.31
16.27 0.87
15.3 1.50
42.78± 6.91
33.82 448b
33.9 4.34
25.55
+1 (8) 4.69 0.31 18.57 2.38 27.05 5.51' 25.47 314b
Both (6) 4.56 0.20 20.14 186b 24.33 2.97" 17.59 2.84"
Nx
+25-OH
(10)
(10)
4.38 0.25
4.90 0.39
16.47 1.82
17.75 2.14
56.5 5.43
34.58 5•57a
41.28 3.01
29.41 3.92"
+1 (8) 4.84 0.46 15.53 1.04 25.75 4.22" 14.08 2.91"
Both (8) 5.05 0.37 18.43 153b 31.28 374C 15.97 0.39"
Abbreviations and symbol: C, control rats; Nx, partially nephrectomized rats; +25-OH, addition of 400 ng/ml of 25-OH cholecalciferol; +1,
addition of 0.01 imi of insulin; Both, the addition of 25-OH cholecalciferol and insulin; ( ), refers to the number of muscles in each group.
a The data are presented as nmoles/mg wet weight of muscle.
b p < 0.05 compared to baseline data.
P < 0.02 compared to baseline data.
d P < 0.01 compared to baseline data.
alteration in muscle function unfortunately remains obscure.
Utilizing an isolated muscle preparation incubated under de-
fined conditions, it has been possible to delineate some of the
factors which govern muscle metabolism of both the normal and
the uremic rat. Data from our laboratory [1] demonstrated
accelerated rates of protein catabolism in uremic muscle as
manifested by increased release rates of the noncatabolizable
amino acids, tyrosine and phenylalanine, as well as alanine.
Addition of pharmacologic levels of insulin restored the acceler-
ated protein catabolism to normal. Metabolic changes compara-
ble to those described in muscles of uremic animals have been
observed in the diabetic (insulinopenic) or cortisol-treated
(insulin resistant) animals [23]. Since circulating insulin levels
are not depressed in uremia, these data are consistent with a
state of insulin resistance with respect to protein metabolism in
muscle. Similar conclusions have been reached on the basis of
carbohydrate and insulin tolerance tests in uremic man [241.
In this study we examined the muscle response to vitamin D.
Clinical reports indicated that the administration of vitamin D
or its metabolites 25(OH)D3 [25] or 1 ,25(OH)2D3 [261 may
dramatically improve muscle function in uremic patients. How-
ever, the role of vitamin D in the maintenance of normal muscle
function has yet to be elucidated adequately. Myopathy is a
prominent feature of nutritional vitamin D deficiency and in the
rachitic experimental animal, vitamin D treatment improves
muscle strength [9] and stimulates a variety of metabolic events
beginning with an enhanced uptake of inorganic phosphate,
increased ATP production, and subsequently increased protein
synthesis [8]. As with insulin, circulating levels of 25(OH)D3
may be normal, yet the uremic patient may experience a
TYR PHE
i
3.0 -
2.5 -
2.0 -
1.5 —
1.0 -
0.5 -
+ +
Insulin Insulin
Fig. 2. Release rates of tyrosine (TYR) and phenylalanine (PHE) from epitrochlearis muscles obtained from control and partially
nephrectomized rats with and without the addition of 100 ng/ml of 25-OH cholecalciferol or 100 ng/,nl of 25-OH cholecalciferol and 0.01 /ml of
insulin.
11
Baseline 25-OH 25-OH Baseline 25-OH 25-OH
Cholecalciferol Cholecalciferol Cholecalciferol Cholecalciferol
BC
a,0
Fig. 4. Rates of leucine incorporation into muscle protein of control and
partial/v nephrectornized rats with and without the addition of 100
ng/ml of 25-OH choleca/ciferol.
profound myopathy. Thus, it would appear clinically that
impaired muscle function in uremia may be partially attributed
to a resistance to vitamin D. A similar resistance has been
postulated for the decreased intestinal absorption of calcium [7]
and the bone disease of uremia [271. Consistent with this
concept of resistance is the fact that several parameters of
muscle metabolism which characterize uremic muscle may be
restored to normal by 25(OH)D3. The concentrations of
25(OH)D3 used in these incubations are approximately five to
six times those of the in vivo levels and are comparable to the
blood levels achieved with vitamin D therapy [281. The mecha-
nism of the resistance of uremic tissue to circulating hormones
including vitamin D remains an important unanswered ques-
tion. In this regard, it is of interest that the muscle clearance
from plasma of tracer 3H-25(OH)D3 was reduced significantly in
uremic animals. This difference could not be attributed to
differences in the circulating concentration of 25(OH)D3. Anal-
ysis confirmed that 99% of the chloroform-methanol extracted
radioactivity in muscle was 25(OH)D3. Thus, accelerated me-
tabolism of the vitamin seems unlikely, suggesting that, indeed,
the rate of accumulation of the vitamin by muscle from uremic
animals may be impaired.
Previous studies from this laboratory demonstrated that the
accelerated release of amino acids from uremic muscle is
limited to alanine and those amino acids which are not catabo-
lized at the level of muscle [1]. The release of these noncataboli-
zable amino acids, tyrosine and phenylalanine, has been used to
assess net protein breakdown. Consequently, the accelerated
rate of release of these amino acids from uremic muscle has
been interpreted to reflect accelerated protein breakdown in the
muscle in the uremic state [1] and is consistent with the
documented increased catabolic rate which characterizes ure-
mia. The influence of 25(OH)D3 on the rate of release of the
above amino acids may also reflect changes in muscle concen-
trations of these amino acids due to alterations in protein
synthetic rates. Under the conditions of these experiments,
25(OH)D3 had no effect on protein synthesis as determined by
the incorporation of 3H-leucine into TCA precipitable protein.
To the extent that 3H-leucine incorporation reflects protein
synthesis, it is depressed initially in the uremic muscle but with
prolonged incubation (3 hr) is restored to normal. The initial
reduced incorporation of 3H-leucine into muscle protein was
not due to reduced uptake secondary to increased tissue pool
sizes of the amino acid. In fact, the tissue levels of leucine were
significantly lower in muscles obtained from uremic rats com-
pared to control values. The addition of 25(OH)D3 did increase
the tissue levels of leucine in muscles from uremic rats but did
not affect the incorporation of this amino acid into TCA
precipitable protein. The reasons for this observation are un-
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Table 3. Cyclic AMP levels in muscles from C and Nx rats incubated with 25-OH cholecalciferol'
Time of
incubation C (7) C + 25-OH (7) Nx (5) Nx + 25-OH (5)
1 hr 117.9 10.5 121.9 7.4 119.1 11.1 118.5 8.9
3 hr 119.3 9.6 103.7 6.4 116.8 10.9 112.9 4.9
Abreviations and symbols: C, muscles from control rats; C + 25-OH, muscles from control rats incubated with 100 ng/ml of 25-OH
cholecalciferol; Nx, muscles from partially nephrectomized rats; Nx + 25-OH, muscles from partially nephrectomized rats incubated with 100 ngl
ml of 25-OH cholecalciferol; ( ), refers to number of muscles in each group.
a The data is presented in pmoles/100 mg wet weight of muscle.
Table 4. Clearance of 3H-25-OH cholecalciferol by muscle
Weight corrected
Weight Blood 3H blood 3H Muscle 3H Muscle
Groupa g cpmlO.1 ml cpmlmllg cpm/glprot clearanceb
C (6) 138 3 958 16 69.4 46.0 46 3
C (6)
+ 1000 ng 25-(OH)D3 138 5 979 20 70.9 48.7 49 2
Nx (6) 124 4 1041 28C 31.7 30 1'
Nx(6)
+1000 ng 25-(OH)D3 124 10 1099 31C 886d 34.2 32 IC
Abbreviations and symbol: C, control rats; Nx, partially nephrectomized rats; ( ), refers to the number of animals in each group.
a All animals given 5 ng 25-(OH)D3 (1.2 x 106 cpm) i.v.
b Muscle (3H)Ig proteinMuscle clearance = X 100.
Blood ( H)/0.l ml
P < 0.01 compared to C values.
d P < 0.05 compared to C values.
clear but may relate to the uremic milieu, other hormones, or
the acid-base status of the animal. The observed decreased
pools of tyrosine and phenylalanine in muscle after 25(OH)D3
was added to the incubating media support the interpretation
that the decreased release of these amino acids can be attribut-
ed appropriately to a specific reduction in protein breakdown.
Thus, the accelerated release of alanine, tyrosine and phenylal-
anine seem unlikely to be due to nonspecific alterations in the
muscle membrane of the nephrectomized animal.
Several potential mechanisms for the action of 25(OH)D3 on
muscle protein metabolism were investigated. It has been
postulated that the expression of vitamin D action on the
intestine may be mediated through the enhanced generation of
cyclic AMP [291. Release of alanine from normal epitrochlearis
muscle has been shown to be suppressed by epinephrine and
serotonin and is associated with an augmented cyclic AMP
response to these hormones [30]. On the other hand, muscle
obtained from uremic rats demonstrate a blunted cyclic AMP
response to epinephrine and serotonin with little or no suppres-
sion of the accelerated alanine release by these hormones [31].
In these studies, baseline cyclic AMP levels were comparable in
epitrochlearis muscles obtained from control and partially
nephrectomized rats. Furthermore, 25(OH)D3 did not affect
these levels suggesting that the effects of this vitamin D
metabolite on muscle are not mediated through stimulation of
adenylate cyclase.
One of the reported effects of vitamin D on the cell is an
enhancement of calcium accumulation [32, 331. Several investi-
gators have provided evidence that vitamin D and specifically
25(OH)D3 may enhance the calcium uptake by the sarcoplasmic
reticulum of muscle [33]. Although it is suggested that the
vitamin stimulated a calcium pump which is associated with the
sarcoplasmic reticulum, the data reported do not exclude the
vitamin's stimulation of calcium transport across the sarcolem-
ma since recent data demonstrated that vitamin D may affect
the binding of calcium to the sarcolemma [34]. The role of
calcium in mediating the action of 25(OH)D3 on muscle may
also explain the difference between the clinical effectiveness of
l,25-(OH)2D3 and the failure of this metabolite to influence
muscle metabolism in vitro. The failure of l,25-(OH)2D3 to
influence muscle function directly can be attributed to the
absence of the specific cytosol receptor protein for this vitamin
D metabolite [35]. This protein would appear to be required for
the action of 1,25 (OH)2D3 consistent with the classic model of
steroid hormone action. However, 1,25 (OH)2D3 is extremely
effective in mobilizing calcium and in uremic man and experi-
mental animals, it may rapidly increase plasma calcium [26, 36].
Thus, one can postulate that 1,25 (OH)2D3, in addition, may
influence muscle function indirectly, perhaps by facilitating the
entry of calcium into muscle or suppressing the release of PTH.
In summary, we have demonstrated that 25(OH)D3 but not
1,25 (OH)2D3 will reduce muscle protein catabolic rates from
muscles obtained from partially nephrectomized rats. No ef-
fects on normal muscle catabolic rates were seen. The effects of
25(OH)D3 on muscle does not appear to be mediated through
stimulation of adenylate cyclase. Furthermore, muscle protein
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synthetic rates were not affected by 25(OH)D3. 25(OH)D3
uptake by uremic muscle was blunted suggesting that resistance
to this vitamin D metabolite exists at the level of muscle.
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